东陽光药

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

ANNOUNCEMENT
POSITIVE PROFIT ALERT

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company hereby informs the shareholders of the Company and potential investors that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company's management, it is expected that the Group will record an increase in profit attributable to equity shareholders of no less than 110% for the six months ended 30 June 2018, as compared to the six months ended 30 June 2017. The expected increase in profit attributable to equity shareholders is primarily attributed to: (i) the significant increase in the sales volume of the Company's key product Kewei and (ii) the continuous optimisation of the Company's academic promotion activities.

The information set out in this announcement is only based on a preliminary assessment by the management of the Company based on the unaudited management accounts of the Group for the six months ended 30 June 2018 and other information currently available to the Company, which has not been reviewed or audited by the Company's auditors. Details on the financial information for the six months ended 30 June 2018 to be disclosed in the interim results announcement of the Company shall prevail.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
9 July 2018

As of the date of this announcement, the Board of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui, Mr. ZHU Qiaohong and Mr. LI Shuang as executive directors; Mr. TANG Xinfa as non-executive director; and Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming as independent non-executive directors.